• By Steven Muntner, Beth Allan, Deanna Kamienski, Amanda Micklus, and Maureen Riordan
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Vermillion Inc. grossed $5.6mm through the private sale of 3.75mm common shares at $1.40 (a 6% premium). Investors also received five-year warrants to buy 2.8mm common at $1.80. The company develops and sells molecular diagnostics for ovarian cancer and other women's health indications. (Feb.)
